menu
    • menu
    [{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Preclinical","graph3":"GRO Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GRO Biosciences \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"GRO Biosciences \/ Atlas Venture"},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"GRO Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"GRO Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"GRO Biosciences \/ Leaps by Bayer"}]

    Find Clinical Drug Pipeline Developments & Deals by GRO Biosciences

    Menu

    GRO Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    GRO Biosciences

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    GRO Biosciences

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Rheumatology

    Study Phase : Preclinical

    Sponsor : Atlas Venture

    Deal Size : $60.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic

    Details : The Proceeds from the financing will be used to advance the Company’s lead program ProGly-Uricase into the clinic for the treatment of refractory gout and to broaden the GRObio pipeline.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    July 19, 2024

    Lead Product(s) : Undisclosed

    Therapeutic Area : Rheumatology

    Highest Development Status : Preclinical

    Sponsor : Atlas Venture

    Deal Size : $60.0 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    GRO Biosciences

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed

    GRO Biosciences

    U.S.A arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Study Phase : Undisclosed

    Sponsor : Leaps by Bayer

    Deal Size : $25.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group

    Details : The proceeds will support development of the GRO platform, scale-up of bioprocess manufacturing, preclinical validation studies and IND-enabling studies for GRObio’s pipeline of unique non-standard amino acid protein therapeutics to treat autoimmune an...

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Undisclosed

    March 11, 2021

    Lead Product(s) : Undisclosed

    Therapeutic Area : Immunology

    Highest Development Status : Undisclosed

    Sponsor : Leaps by Bayer

    Deal Size : $25.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth